Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (15µg/0.5ml)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteers aged ≥3 years;~* Proven legal identity;~* Participants or (and) guardians of the participants should be capable of understanding the written consent form, and such form should be signed prior to enrolment;~Exclusion Criteria:~* Prior vaccination with influenza vaccine of the current year;~* History of influenza within 6 months prior to study entry;~* Axillary temperature \> 37.0 °C;~* History of allergy to any vaccine, or any ingredient of the experimental vaccine, especially eggs, egg albumin, etc.;~* Serious adverse reaction(s) to vaccination, such as urticaria, dyspnea, angioneurotic edema, abdominal pain, etc.;~* Severe/uncontrollable nervous system disease (epilepsy, seizures or convulsions) or mental illness;~* Autoimmune disease or immunodeficiency/immunosuppressive, or any immunosuppressant receipt within 6 months prior to the study entry;~* History of asthma, thyroidectomy, angioedema, diabetes or malignancy;~* No spleen, or functional no spleen, or splenectomy.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Experimental group-phase I (Type: EXPERIMENTAL): Quadrivalent influenza vaccine
- Experimental group-phase III (Type: EXPERIMENTAL): Quadrivalent influenza vaccine
- Control group-1-phase III (Type: ACTIVE_COMPARATOR): Trivalent influenza vaccine (contains B/Victoria strain)
- Control group-2-phase III (Type: ACTIVE_COMPARATOR): Trivalent influenza vaccine (contains B/Yamagata strain)

Based on this trial design, predict the completion outcome and termination type (if applicable).